LUNAPHORE-TECHNOLOGIES
14.1.2021 14:02:40 CET | Business Wire | Press release
Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the formation of its Scientific Advisory Board (SAB) with the appointment of two experts in the immuno-oncology (I-O) field to provide strategic advisory support to the company’s R&D activities and product portfolio development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005435/en/
The role of the SAB will be to bring strategic insights that will enable Lunaphore to become leaders in the field of high-dimensional analysis of tissue samples. The SAB will support as well in the establishment of scientific partnerships with key stakeholders for the coming years.
The new Lunaphore SAB will be comprised of the following members:
- Prof. Paolo A. Ascierto, MD
Dr. Paolo A. Ascierto is the Director of the Department of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Tumor Institute in Naples, Italy. Professor Ascierto’s research interests include the genetics and proteomics of melanoma, assessment of new molecular markers for tumor progression, biochemical and immunological monitoring, immunotherapy and vaccination treatments in solid tumors, and combination strategies with I-O. He is a member of the Steering Committee of Society of Melanoma Research (SMR) and the Board of Directors of Society of ImmunoTherapy of Cancer (SITC), President of the Fondazione Melanoma Onlus, and of Campania Society of ImmunoTherapy of Cancer (SCITO). He is an Associate Editor for Onco-Immunology of Annals of Oncology, Chief Section Editor for Combination Strategies section of Journal of Translational Medicine, and Associate Editor of Journal of ImmunoTherapy of Cancer. He has been the Principal Investigator in over 100 clinical trials and is the author of more than 450 publications in peer-reviewed journals.
- Dr. Jérôme Galon
Dr. Jérôme Galon is the Director of Research at INSERM (French National Institute of Health and Medical Research), and Head of the Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center in Paris, France. Dr. Galon defined the concept of cancer immune-contexture, pioneered the Immunoscore and is PI of the Immunoscore worldwide consortium. This scientific contribution was acknowledged by many awards such as the William B. Coley Award, the Award from the National Academy of Science, from the National Academy of Medicine, and European Inventor Award 2019. He is the co-founder of HalioDx and the Chairman of its Scientific Council.
“I am excited to have such great experts in I-O join our SAB,” said Dr. Dupouy, CTO at Lunaphore. “Their expertise in the field will be key to focus our research efforts on the most promising I-O applications, as well as to expand our scientific collaborations worldwide.”
"The key for the immune responsiveness is in the tumor microenvironment,” noted Dr. Ascierto. “Lunaphore has a technology which can potentially make such evaluation easier and greatly contribute to the research field of immunotherapy."
“Lunaphore is developing rapid automated staining instruments based on an innovative microfluidic technology with great potential for multiple research applications,” Dr. Galon said. “I look forward to the next generation hyper-plex immunofluorescence instruments.”
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company transforming the field of tissue analytics in cancer research through the development of innovative staining and imaging technology platforms. The award-winning technology at its core is called FFeX (Fast Fluidic Exchange). Using high-precision microfluidics, complex assays can be automated, extracting comprehensive data much faster than current techniques. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue analytics and has been recognized as one of the most innovative companies internationally. For further information on Lunaphore and its products, please visit www.lunaphore.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005435/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MultiBank Group Named Most Regulated Global Financial Derivatives Institution.3.9.2026 13:47:00 CEST | Press release
MultiBank Group has won the Most Regulated Global Financial Derivatives Institution Award at Money Expo India 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903046526/en/ MultiBank Group has won the Most Regulated Global Financial Derivatives Institution Award at Money Expo India 2026. The award highlights MultiBank Group’s strong global regulatory framework as it holds more than 18 regulatory licences across five continents, including the Australian Securities and Investments Commission (ASIC), the German Federal Financial Supervisory Authority (BaFin), the Cyprus Securities and Exchange Commission (CySEC), the UAE’s Capital Market Authority (CMA), reflecting its longstanding commitment to governance, compliance and transparency. The latest recognition adds to MultiBank Group’s growing award portfolio of more than 80 international industry awards, spanning areas including financial services, trading technology, reg
Humanoids Dominate the Headlines, but Specialized Physical AI Captures Value in $18 Billion Market, Arthur D. Little’s Blue Shift Finds3.9.2026 12:07:00 CEST | Press release
Arthur D. Little’s (ADL) Blue Shift, its forward-looking institute exploring the impact of emerging technologies on business and society, today published I, Robot. Despite the hype around humanoid robots, this report finds they are still immature, compared to other areas of physical AI (autonomous and versatile robots that can perceive, decide, and act in the physical world). ADL analysis shows that humanoid robots only account for $2-3 billion of today’s overall $18 billion physical AI market. Many demonstrations are pre-programmed, remotely operated or even totally AI-generated. The study highlights that specialized physical AI offers the real opportunity for innovation and value in the short-to-medium term, and that businesses should take action now. The overall market could reach $60-$100 billion by 2030, thanks to drivers including labor shortages, shifting work preferences, increasing needs for operational resilience and productivity pressures. Countries and regions are competing
LITEON Announces Strategic Investment in Liquid Cooling Technology Company DCX3.9.2026 12:05:00 CEST | Press release
Advancing AI Infrastructure Value Chain Through Integrated Power Management and Cooling Technologies LITEON Technology (2301.TW) today announced a strategic investment in DCX POLSKA Sp. z o.o. (“DCX Liquid Cooling Systems”), a Warsaw, Poland-based provider of advanced liquid cooling systems for AI and High-Performance Computing (HPC) data centers. Upon closing of the transaction, LITEON will hold approximately 25% equity ownership in DCX Liquid Cooling Systems with a total transaction value of approximately US$176 million. The investment brings together DCX's deep expertise in liquid cooling technologies, including coolant distribution units (CDUs), facility coolant distribution units (FDUs), cold plates and immersion cooling systems, with LITEON's strengths in AI server power management, rack-level power delivery and 800VDC power architectures. Together, the two companies are positioned to deliver highly integrated power and thermal management solutions for the rapidly evolving AI inf
The Untold Story ‘NEW YORK IN MONCLER’3.9.2026 12:00:00 CEST | Press release
A Retrospective of Pioneering New York Moments Some love stories take time. After decades of shared moments, Moncler reveals the story of its enduring relationship with New York through an expansive city-wide declaration of love. The untold story of New York in Moncler began when snow met concrete. What could have melted instead endured, forging a love built on pioneering moments and strengthened with every chapter. They found each other, again and again. Decades later, their story is finally ready to be shared. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903671495/en/ NEW YORK IN MONCLER MIDTOWN MOUNTAINS Revealed through one of the largest open-air public exhibitions the city has ever seen, New York in Monclerunveils the peak moments that capture the bond between New York and Moncler, transforming communal spaces across the city into a powerful retrospective gallery from September 9-13. New York in Moncleris a very p
Chiesi Advances Its Carbon Minimal Inhaler Journey as European Submissions for Its Single Inhaler Triple Therapy (SITT) and ICS/LABA Combination Next-Generation Propellant pMDIs Are Validated3.9.2026 11:00:00 CEST | Press release
Key Highlights Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi’s Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed double ICS/LABA combination (inhaled corticosteroid with a long-acting bronchodilator) range have been validated by Regulatory Agencies in Europe. Transition to HFA‑152a, a next‑generation propellant classified as non‑PFAS* and with low global warming potential (GWP),aimsto reduce the carbon footprint of Chiesi’s pMDIs by up to 90% compared to current ones.1-3 Designed for a seamless transition for patients and HCPs, maintaining established efficacy, safety and usability and supporting continuity of care.4-8 The validation supports Chiesi’s ambition to reach Net Zero† across its full value chain by 20359, following MHRA approval of Chiesi’s beclometasone pMDIs formulated with HFA-152a. Chiesi Group, an international research-focused biopharmaceutical company and certified B Corp, today announces a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom